Tecemotide
- Generic Name
- Tecemotide
- Drug Type
- Biotech
- CAS Number
- 221214-84-2
- Unique Ingredient Identifier
- Q7Y026G2CX
- Background
Tecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung.
Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
Phase 3
Terminated
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2017-08-23
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 35
- Registration Number
- NCT02049151
- Locations
- 🇺🇸
Please Contact U.S. Medical Information Located in, Rockland, Massachusetts, United States
🇩🇪Please contact the Merck KGaA Communication Center Located in, Darmstadt, Germany
Tecemotide (L-BLP25) in Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 28
- Registration Number
- NCT01496131
- Locations
- 🇺🇸
Please Contact US Medical Information, Rockland, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath